NEH

Updates to FDA and Clinical Trial Calendars

What part of the body produces liraglutide. Reply if you can, and I will have a look at your website. Thanks BioMedReports.com!


On Mar 08 03:09 PM BioMedReports.com wrote:

> Victoza (liraglutide) is used once-daily via subcutaneous injection.
> Liraglutide is a synthetic glucagons-like peptide-1 (GLP-1) and is
> classified as an incretin mimetic type of diabetes drug. GLP-1 is
> a gut-derived regulator of glucose that is released after oral ingestion
> of carbohydrates or gats. Type 2 diabetics have reduced levels of
> GLP-1 in response to carbohydrate intake.
>
> GLP-1 enhances insulin secretion once it enters the systemic circulation
> and also increases the synthesis of insulin. Other effects of GLP-1
> include suppression of glucagon secretion, slower gastric emptying
> (5-10% incidence of nausea), reduced food/caloric intake, and pancreatic
> beta cell proliferation. Liraglutide does not increase insulin secretion
> or suppress glucagons secretion when blood glucose levels are low
> or normal.
>
> Symlin (pramlintide) is used via subcutaneous injection prior to
> meals as a synthetic analog of the hormone amylin which is secreted
> by the pancreatic beta cells along with insulin in health individuals
> (amylin is secreted at much lower levels than insulin, e.g. 1:20
> ratio). Amylin secretion is absent in Type 1 diabetics and decreased
> in Type 2 diabetics. Decreased or absent amylin secretion results
> in inadequate response to insulin treatments leading to weight gain
> and poor glycemic control (especially after meals or postprandial).
>
>
> Amylin replacement therapy results in slower gastric emptying (nausea
> side effect results), decreased appetite/caloric intake, and decreased
> glucagon secretion after meals. In combination with insulin, Symlin
> treatment results in better glycemic control and causes modest weight
> loss (versus weight gain associated with insulin mono-therapy).
>